Ridaforolimus
Phase 3Small molecule
Merck & Co.Ridaforolimus is a small molecule that works as a Serine/threonine-Protein Kinase MTOR Inhibitor.[2] It is being investigated across 12 indications, with its most advanced program in Phase 3.[1]
Ridaforolimus is one of 346 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.
12
Indications
33
Total Trials
0
Active Trials
345
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ridaforolimus
Merck & Co.Phase 3
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer4 trials
Advanced Cancer4 trials
Endometrial Cancer2 trials
Prostate Cancer2 trials
17 more indications
Soft Tissue Sarcoma2 trials
Advanced Solid Tumors2 trials
Relapsed or Refractory Hematologic Malignancies1 trial
Advanced Malignancies1 trial
Treatment1 trial
Head Neck Cancer1 trial
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Terminated·—·Phase 1·NCT01212627·12 enrolled
Advanced Sarcoma1 trial
Advanced Cancers1 trial
Maximum Tolerated Dose1 trial
Solid Tumors1 trial
Endometrial Carcinoma1 trial
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ridaforolimus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serine/threonine-Protein Kinase MTOR Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company